Tarapeutics Science Inc.

Ao Li Wang

Jing Liu

Li Wang

Wen Chao Wang

Cheng Chen

Chen Hu

Xi Li

Wen Liang Wang

Zi Ping Qi

Feng Ming Zou

Qing Song Liu

Qing Wang Liu

Bei Lei Wang

Qingsong Liu

Tao Ren

Shuang Qi

Juan Liu

Zong Ru Jiang

Xiao Fei Liang

Jiang Yan Cao

Fengchao Lv

Xi Xiang Li

Provided is a novel PDGFR kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Further provided are use and a method of the compound of formula (I) for preventing or treating conditions associated with PDGFR kinase activity, particularly use and a method for preventing or treating conditions associated with PDGFRα and/or PDGFRβ kinase activity.

Pyrazole derivatives and use thereof

The present invention provides a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a use or method of the compound of formula (I) in the treatment or prevention of a disorder related to the activity of RAF and/or RAS kinase.

Pan-RAF kinase inhibitor and use thereof

An inhibitor of a wild type and Y641F mutant of human histone methyltransferase EZH2 is provided herein. Particularly, the inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The inhibitor can be used to treat a cancer or precancerous condition related to EZH2 activity. 

EZH2 inhibitor and use thereof

Growing community of inventors

Anhui, China

Ao Li Wang